Pharmafile Logo
Pharmafocus logo
Advanced Search

MS

Showing 15 posts of 92 posts found.

NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons

December 20, 2017
Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

News
roche_dark_0

EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis

November 13, 2017
Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

News
novartis_side_building

Novartis celebrates success of Gilenya in paediatric multiple sclerosis

September 5, 2017
Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …

News
shutterstock_236161768

Novartis launches first large-scale smartphone-based study in multiple sclerosis

August 23, 2017
Research and Development MS, Novartis, life sciences, multiple sclerosis, pharma, pharmaceuticals

Novartis has launched what it claims is the first large-scale mobile research study which will gather data on multiple sclerosis …

News
folder

Common treatment for MS revealed to have potential adverse reactions

May 16, 2017
Manufacturing and Production, Research and Development MS, multiple sclerosis

Beta interferons are a common treatment used to manage multiple sclerosis. The treatment works by reducing and preventing the inflammation …

News
roche_close

First treatment for form of MS approved by FDA

March 30, 2017
Sales and Marketing Biogen, Genentech, MS, Roche

In big news for sufferers of MS and the company that developed the drug, Roche subsidiary Genetech, the FDA has …

News
roche__tree

Roche’s ground-breaking MS drug delayed by manufacturing issues

December 22, 2016
Genentech, MS, Roche, multiple sclerosis

Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …

News
biogen_austria_238

Biogen MS drug misses primary endpoint in Phase II trial

June 8, 2016
Research and Development Biogen, MS, multiple sclerosis, opicinumab

Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …

News

FDA gives Roche MS drug breakthrough status

February 17, 2016
Research and Development Genentech, MS, Roche

Roche subsidiary Genentech has been awarded US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its drug Ocrevus (ocrelizumab) …

News
Genentech logo

Positive late-stage results for Genentech’s ocrelizumab in different forms of MS

October 8, 2015
Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab

Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …

News
Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015
Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …

News
aubagio

Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial

October 7, 2015
Research and Development Genzyme, MS, Sanofi

Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …

News

Genentech’s ocrelizumab shows efficacy in phase III trial

September 30, 2015
Research and Development Genentech, MS, Roche, ocrelizumab

Roche subsidiary Genentech has announced positive results from a pivotal phase III study of its investigational medicine ocrelizumab in people …

News

Biogen to build billion-dollar plant in Switzerland

July 7, 2015
Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis

Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …

News

Novartis MS drug scores positive late-stage trial result

April 21, 2015
Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis

People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025